Metformin can activate imidazoline I-2 receptors to lower plasma glucose in type 1-like diabetic rats

J. P. Lee, W. Chen, H. T. Wu, K. C. Lin, J. T. Cheng

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Metformin is widely used in clinic for handling the diabetic disorders. However, action mechanisms of metformin remain obscure. It has recently been indicated that guanidinium derivatives are ligands to activate type-2 imidazoline receptors (I-2 receptors) that can improve diabetes through increment in skeletal muscle glucose uptake. Also, activation of I-2 receptors can increase the release of β-endorphin in diabetic animals. Because metformin is a guanidinium derivative, we were interested in the effect of metformin on I-2 receptors. In the present study, the marked blood glucose-lowering action of metformin in streptozotocin-induced type-1 like diabetes rats was blocked by specific I-2 receptor antagonist, BU224, in a dose-dependent manner. Also, the increase of β-endorphin release by metformin was blocked by BU224 in same manner. A specific competition between metformin and BU224 was observed in isolated adrenal medulla. Otherwise, amiloride at the dose sufficient to block I-2A receptor abolished the metformin-induced β-endorphin release, but only the blood glucose-lowering action of metformin was markedly reduced. In addition, the blood glucose-lowering action of metformin in bilateral adrenalectomized rats was diminished by amiloride at higher doses. These results suggest that metformin might activate imidazoline I-2 receptors while I-2A receptors link the increase of β-endorphin release and I-2B receptors couple to the other actions for lowering of blood glucose in type-1 like diabetic rats.

Original languageEnglish
Pages (from-to)26-30
Number of pages5
JournalHormone and Metabolic Research
Volume43
Issue number1
DOIs
Publication statusPublished - Jan 1 2011
Externally publishedYes

Fingerprint

Imidazolines
Metformin
Rats
Plasmas
Glucose
Endorphins
Blood Glucose
Amiloride
Guanidine
Medical problems
imidazoline receptor 2
Derivatives
Adrenal Medulla
Streptozocin
Type 1 Diabetes Mellitus
Muscle
Animals
Skeletal Muscle
Chemical activation

Keywords

  • -endorphin
  • amiloride
  • diabetes
  • imidazoline receptor
  • metformin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Metformin can activate imidazoline I-2 receptors to lower plasma glucose in type 1-like diabetic rats. / Lee, J. P.; Chen, W.; Wu, H. T.; Lin, K. C.; Cheng, J. T.

In: Hormone and Metabolic Research, Vol. 43, No. 1, 01.01.2011, p. 26-30.

Research output: Contribution to journalArticle

@article{36ee357d78634d89897ab5fca6d407f4,
title = "Metformin can activate imidazoline I-2 receptors to lower plasma glucose in type 1-like diabetic rats",
abstract = "Metformin is widely used in clinic for handling the diabetic disorders. However, action mechanisms of metformin remain obscure. It has recently been indicated that guanidinium derivatives are ligands to activate type-2 imidazoline receptors (I-2 receptors) that can improve diabetes through increment in skeletal muscle glucose uptake. Also, activation of I-2 receptors can increase the release of β-endorphin in diabetic animals. Because metformin is a guanidinium derivative, we were interested in the effect of metformin on I-2 receptors. In the present study, the marked blood glucose-lowering action of metformin in streptozotocin-induced type-1 like diabetes rats was blocked by specific I-2 receptor antagonist, BU224, in a dose-dependent manner. Also, the increase of β-endorphin release by metformin was blocked by BU224 in same manner. A specific competition between metformin and BU224 was observed in isolated adrenal medulla. Otherwise, amiloride at the dose sufficient to block I-2A receptor abolished the metformin-induced β-endorphin release, but only the blood glucose-lowering action of metformin was markedly reduced. In addition, the blood glucose-lowering action of metformin in bilateral adrenalectomized rats was diminished by amiloride at higher doses. These results suggest that metformin might activate imidazoline I-2 receptors while I-2A receptors link the increase of β-endorphin release and I-2B receptors couple to the other actions for lowering of blood glucose in type-1 like diabetic rats.",
keywords = "-endorphin, amiloride, diabetes, imidazoline receptor, metformin",
author = "Lee, {J. P.} and W. Chen and Wu, {H. T.} and Lin, {K. C.} and Cheng, {J. T.}",
year = "2011",
month = "1",
day = "1",
doi = "10.1055/s-0030-1267169",
language = "English",
volume = "43",
pages = "26--30",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "1",

}

TY - JOUR

T1 - Metformin can activate imidazoline I-2 receptors to lower plasma glucose in type 1-like diabetic rats

AU - Lee, J. P.

AU - Chen, W.

AU - Wu, H. T.

AU - Lin, K. C.

AU - Cheng, J. T.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Metformin is widely used in clinic for handling the diabetic disorders. However, action mechanisms of metformin remain obscure. It has recently been indicated that guanidinium derivatives are ligands to activate type-2 imidazoline receptors (I-2 receptors) that can improve diabetes through increment in skeletal muscle glucose uptake. Also, activation of I-2 receptors can increase the release of β-endorphin in diabetic animals. Because metformin is a guanidinium derivative, we were interested in the effect of metformin on I-2 receptors. In the present study, the marked blood glucose-lowering action of metformin in streptozotocin-induced type-1 like diabetes rats was blocked by specific I-2 receptor antagonist, BU224, in a dose-dependent manner. Also, the increase of β-endorphin release by metformin was blocked by BU224 in same manner. A specific competition between metformin and BU224 was observed in isolated adrenal medulla. Otherwise, amiloride at the dose sufficient to block I-2A receptor abolished the metformin-induced β-endorphin release, but only the blood glucose-lowering action of metformin was markedly reduced. In addition, the blood glucose-lowering action of metformin in bilateral adrenalectomized rats was diminished by amiloride at higher doses. These results suggest that metformin might activate imidazoline I-2 receptors while I-2A receptors link the increase of β-endorphin release and I-2B receptors couple to the other actions for lowering of blood glucose in type-1 like diabetic rats.

AB - Metformin is widely used in clinic for handling the diabetic disorders. However, action mechanisms of metformin remain obscure. It has recently been indicated that guanidinium derivatives are ligands to activate type-2 imidazoline receptors (I-2 receptors) that can improve diabetes through increment in skeletal muscle glucose uptake. Also, activation of I-2 receptors can increase the release of β-endorphin in diabetic animals. Because metformin is a guanidinium derivative, we were interested in the effect of metformin on I-2 receptors. In the present study, the marked blood glucose-lowering action of metformin in streptozotocin-induced type-1 like diabetes rats was blocked by specific I-2 receptor antagonist, BU224, in a dose-dependent manner. Also, the increase of β-endorphin release by metformin was blocked by BU224 in same manner. A specific competition between metformin and BU224 was observed in isolated adrenal medulla. Otherwise, amiloride at the dose sufficient to block I-2A receptor abolished the metformin-induced β-endorphin release, but only the blood glucose-lowering action of metformin was markedly reduced. In addition, the blood glucose-lowering action of metformin in bilateral adrenalectomized rats was diminished by amiloride at higher doses. These results suggest that metformin might activate imidazoline I-2 receptors while I-2A receptors link the increase of β-endorphin release and I-2B receptors couple to the other actions for lowering of blood glucose in type-1 like diabetic rats.

KW - -endorphin

KW - amiloride

KW - diabetes

KW - imidazoline receptor

KW - metformin

UR - http://www.scopus.com/inward/record.url?scp=78650959848&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650959848&partnerID=8YFLogxK

U2 - 10.1055/s-0030-1267169

DO - 10.1055/s-0030-1267169

M3 - Article

C2 - 20945271

AN - SCOPUS:78650959848

VL - 43

SP - 26

EP - 30

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 1

ER -